Quest Diagnostics has received FDA Breakthrough Device Designation for its circulating tumor DNA (ctDNA) test aimed at minimal residual disease (MRD) detection in colorectal cancer patients. Acquired through Haystack Oncology in 2023, this assay allows earlier detection of residual cancer, potentially guiding personalized adjuvant therapies and improving outcomes in colorectal cancer management.